A review of targeted pulmonary arterial hypertension-specific pharmacotherapy

Journal of Clinical Medicine

Volumn 5, Issue 12, 2016, Pages

  Ataya, Ali ^a   Cope, Jessica ^a   Alnuaimat, Hassan ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Endothelin; Nitric oxide; Prostacyclin; Pulmonary arterial hypertension; Pulmonary hypertension; Soluble guanylate cyclase

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GUANYLATE CYCLASE; ILOPROST; MACITENTAN; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; TREPROSTINIL;

ANEMIA; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE COURSE; DIZZINESS; DYSPEPSIA; EXERCISE; GENE OVEREXPRESSION; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; JAW PAIN; NAUSEA; NAUSEA AND VOMITING; NOSE OBSTRUCTION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PULMONARY HYPERTENSION; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; SIX MINUTE WALK TEST; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85029671356     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5120114     Document Type: Review

References (40)

1. Taichman, D.B.; Ornelas, J.; Chung, L.; Klinger, J.R.; Lewis, S.; Mandel, J.; Palevsky, H.I.; Rich, S.; Sood, N.; Rosenzweig, E.B. et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 2014, 146, 449-475.
2. Galie, N.; Ghofrani, H.A.; Torbicki, A.; Barst, R.J.; Rubin, L.J.; Badesch, D.; Fleming, T.; Parpia, T.; Burgess, G.; Branzi, A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005, 353, 2148-2157.
3. Sildenafil (Package Insert); Pfizer: New York, NY, USA, 1998.
4. Ishikura, F.; Beppu, S.; Hamada, T.; Khandheria, B.K.; Seward, J.B.; Nehra, A. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation 2000, 102, 2516-2521.
5. Simonneau, G.; Rubin, L.J.; Galie, N.; Barst, R.J.; Fleming, T.R.; Frost, A.; Engel, P.; Kramer, M.R.; Serdarevic-Pehar, M.; Layton, G.R. et al. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J. Heart Lung Transplant. 2014, 33, 689-697.
6. McLaughlin, V.; Channick, R.N.; Ghofrani, H.A.; Lemarie, J.C.; Naeije, R.; Packer, M.; Souza, R.; Tapson, V.F.; Tolson, J.; AlHiti, H. et al. Bosentan added to sildenafil therapy in patientswith pulmonary arterial hypertension. Eur. Respir. J. 2015, 46, 405-413.
7. Kloner, R.A.; Hutter, A.M.; Emmick, J.T.; Mitchell, M.I.; Denne, J.; Jackson, G. Time course of the interaction between tadalafil and nitrates. J. Am. Coll. Cardiol. 2003, 42, 1855-1860.
8. Tadalafil (Package Insert); Eli Lilly and Company: Indianapolis, IN, USA, 2003.
9. Galie, N.; Brundage, B.H.; Ghofrani, H.A.; Oudiz, R.J.; Simonneau, G.; Safdar, Z.; Shapiro, S.; White, R.J.; Chan, M.; Beardsworth, A. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119, 2894-2903.
10. Oudiz, R.J.; Brundage, B.H.; Galie, N.; Ghofrani, H.A.; Simonneau, G.; Botros, F.T.; Chan, M.; Beardsworth, A.; Barst, R.J.; Group, P.S. Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52-week uncontrolled extension study. J. Am. Coll. Cardiol. 2012, 60, 768-774.
11. Galie, N.; Barbera, J.A.; Frost, A.E.; Ghofrani, H.A.; Hoeper, M.M.; McLaughlin, V.V.; Peacock, A.J.; Simonneau, G.; Vachiery, J.L.; Grunig, E. et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N. Engl. J. Med. 2015, 373, 834-844.
12. Riociguat (Package Insert); Bayer HealthCare Pharmaceuticals: Whippany, NJ, USA, 2013.
13. Ghofrani, H.A.; D’Armini, A.M.; Grimminger, F.; Hoeper, M.M.; Jansa, P.; Kim, N.H.; Mayer, E.; Simonneau, G.; Wilkins, M.R.; Fritsch, A. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 2013, 369, 319-329.
14. Ghofrani, H.A.; Galie, N.; Grimminger, F.; Grunig, E.; Humbert, M.; Jing, Z.C.; Keogh, A.M.; Langleben, D.; Kilama, M.O.; Fritsch, A. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2013, 369, 330-340.
15. Waxman, A.B.; Zamanian, R.T. Pulmonary arterial hypertension: New insights into the optimal role of current and emerging prostacyclin therapies. Am. J. Cardiol. 2013, 111 (Suppl 5), 1A-16A.
16. Bosentan (Package Insert); Actelion: South San Francisco, CA, USA, 2001.
17. Galie, N.; Beghetti, M.; Gatzoulis, M.A.; Granton, J.; Berger, R.M.; Lauer, A.; Chiossi, E.; Landzberg, M. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006, 114, 48-54.
18. Channick, R.N.; Simonneau, G.; Sitbon, O.; Robbins, I.M.; Frost, A.; Tapson, V.F.; Badesch, D.B.; Roux, S.; Rainisio, M.; Bodin, F. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001, 358, 1119-1123.
19. Rubin, L.J.; Badesch, D.B.; Barst, R.J.; Galie, N.; Black, C.M.; Keogh, A.; Pulido, T.; Frost, A.; Roux, S.; Leconte, I. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002, 346, 896-903.
20. Galie, N.; Rubin, L.; Hoeper, M.; Jansa, P.; Al-Hiti, H.; Meyer, G.; Chiossi, E.; Kusic-Pajic, A.; Simonneau, G. Treatment of patientswithmildly symptomatic pulmonary arterial hypertensionwith bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet 2008, 371, 2093-2100.
21. Ambrisentan (Package Insert); Gilead Sciences: Foster City, CA, USA, 2007.
22. Galie, N.; Olschewski, H.; Oudiz, R.J.; Torres, F.; Frost, A.; Ghofrani, H.A.; Badesch, D.B.; McGoon, M.D.; McLaughlin, V.V.; Roecker, E.B. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117, 3010-3019.
23. Pulido, T.; Adzerikho, I.; Channick, R.N.; Delcroix, M.; Galie, N.; Ghofrani, H.A.; Jansa, P.; Jing, Z.C.; Le Brun, F.O.; Mehta, S. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 2013, 369, 809-818.
24. Macitentan (Package Insert); Actelion: South San Francisco, CA, USA, 2013.
25. McLaughlin, V.V.; Archer, S.L.; Badesch, D.B.; Barst, R.J.; Farber, H.W.; Lindner, J.R.; Mathier, M.A.; McGoon, M.D.; Park, M.H.; Rosenson, R.S. et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119, 2250-2294.
26. FLOLAN (R) (Package Insert); GlaxoSmithKline: Research Triangle Park, NC, USA, 1995.
27. VELETRI (R) (Package Insert); Actelion Pharmaceuticals US, Inc.: South San Francisco, CA, USA, 1995.
28. Barst, R.J.; Rubin, L.J.; Long, W.A.; McGoon, M.D.; Rich, S.; Badesch, D.B.; Groves, B.M.; Tapson, V.F.; Bourge, R.C.; Brundage, B.H. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med. 1996, 334, 296-301.
29. McLaughlin, V.V.; Shillington, A.; Rich, S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002, 106, 1477-1482.
30. REMODULIN (R) (Package Insert); United Therapeutics Corporation: Research Triangle Park, NC, USA, 2002.
31. Hiremath, J.; Thanikachalam, S.; Parikh, K.; Shanmugasundaram, S.; Bangera, S.; Shapiro, L.; Pott, G.B.; Vnencak-Jones, C.L.; Arneson, C.; Wade, M. et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial. J. Heart Lung Transplant. 2010, 29, 137-149.
32. Simonneau, G.; Barst, R.J.; Galie, N.; Naeije, R.; Rich, S.; Bourge, R.C.; Keogh, A.; Oudiz, R.; Frost, A.; Blackburn, S.D. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2002, 165, 800-804.
33. Olschewski, H.; Simonneau, G.; Galie, N.; Higenbottam, T.; Naeije, R.; Rubin, L.J.; Nikkho, S.; Speich, R.; Hoeper, M.M.; Behr, J. et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 2002, 347, 322-329.
34. McLaughlin, V.V.; Benza, R.L.; Rubin, L.J.; Channick, R.N.; Voswinckel, R.; Tapson, V.F.; Robbins, I.M.; Olschewski, H.; Rubenfire, M.; Seeger, W. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J. Am. Coll. Cardiol. 2010, 55, 1915-1922.
35. Jing, Z.C.; Parikh, K.; Pulido, T.; Jerjes-Sanchez, C.; White, R.J.; Allen, R.; Torbicki, A.; Xu, K.F.; Yehle, D.; Laliberte, K. et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial. Circulation 2013, 127, 624-633.
36. Ventavis (R) (Package Insert); Actelion Pharmaceuticals US, Inc.: South San Francisco, CA, USA, 2004.
37. Tapson, V.F.; Torres, F.; Kermeen, F.; Keogh, A.M.; Allen, R.P.; Frantz, R.P.; Badesch, D.B.; Frost, A.E.; Shapiro, S.M.; Laliberte, K. et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): A randomized controlled trial. Chest 2012, 142, 1383-1390.
38. Tapson, V.F.; Jing, Z.C.; Xu, K.F.; Pan, L.; Feldman, J.; Kiely, D.G.; Kotlyar, E.; McSwain, C.S.; Laliberte, K.; Arneson, C. et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): A randomized controlled trial. Chest 2013, 144, 952-958.
39. Selexipag (Package Insert); Actelion: South San Francisco, CA, USA, 2015.
40. Sitbon, O.; Channick, R.; Chin, K.M.; Frey, A.; Gaine, S.; Galie, N.; Ghofrani, H.A.; Hoeper, M.M.; Lang, I.M.; Preiss, R. et al. Selexipag for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2015, 373, 2522-2533.